Lifecore Biomedical Inc

Long- and medium-term trends remain bearish under Stage 4 with a clear series of lower highs and lower lows beneath declining EMAs and SMAs. Short-term timing is unfavorable for long-side participation as price repeatedly rejects the 9- and 20-day EMAs and tracks below structure without oversold exhaustion. No inflection or mean-reversion patterns are active, reinforcing the persistence of downward momentum. Execution is appropriate now by selling on rallies into the resistance cluster around the 20-day EMA and 50-day SMA, with key support near recent lows in the $4.35 6 4.40 range.

• ↑Q3 revenue rose 26% YoY to $31.1M with 11 late-stage programs by 2028
• ↑SG&A cut 40% YoY to $8.9M drove adjusted EBITDA to $8.6M in Q2
• ↓FY 2025 net loss $34.5M; Q2 loss widened to $6.2M